Reply to rituximab activity in CD20 positive multiple myeloma

被引：4
|
作者：
Gozzetti, A. [1 ]
Fabbri, A.
Lazzi, S.
Bocchia, M.
Lauria, F.
机构：
[1] Univ Siena, Dept Med & Immunol Sci, Div Hematol & Transplants, I-53100 Siena, Italy
[2] Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy
来源：
LEUKEMIA | 2007年 / 21卷 / 08期
关键词：
D O I：
10.1038/sj.leu.2404702
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1842 / 1843
页数：2
相关论文
共 50 条
  • [41] The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
    Teeling, Jessica L.
    Mackus, Wendy J. M.
    Wiegman, Luus J. J. M.
    van den Brakel, Jeroen H. N.
    Beers, Stephen A.
    French, Ruth R.
    van Meerten, Tom
    Ebeling, Saskia
    Vink, Tom
    Slootstra, Jerry W.
    Parren, Paul W. H. I.
    Glennie, Martin J.
    van de Winkel, Jan G. J.
    JOURNAL OF IMMUNOLOGY, 2006, 177 (01): : 362 - 371
  • [42] Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy
    Korte, W
    Jost, C
    Cogliatti, S
    Hess, U
    Cerny, T
    ANNALS OF ONCOLOGY, 1999, 10 (10) : 1249 - 1250
  • [43] Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris
    El Tal, Abdul Kader
    Posner, Marshall R.
    Spigelman, Zachary
    Ahmed, A. Razzaque
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (03) : 449 - 459
  • [44] CD20 positive mycosis fungoides: a case report
    Sen, Filiz
    Kang, Steven
    Cangiarella, Joan
    Kamino, Hideko
    Hymes, Kenneth
    JOURNAL OF CUTANEOUS PATHOLOGY, 2008, 35 (04) : 398 - 403
  • [45] Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: A pilot series
    Chevallier, Patrice
    Pigneux, Arnaud
    Robillard, Nelly
    Ayari, Sameh
    Guillaume, Thierry
    Delaunay, Jacques
    Eveillard, Marion
    Dumas, Pierre-Yves
    Lippert, Eric
    Mohty, Mohamad
    Leguay, Thibaut
    LEUKEMIA RESEARCH, 2012, 36 (03) : 311 - 315
  • [46] Phase II individualized pharmacokinetic (PK) dosing of rituximab for patients with CD20 positive lymphoproliferative disorders.
    Lynch, JW
    Pusateri, A
    Balasubramanian, L
    Mendenhall, N
    Grow, B
    BLOOD, 2001, 98 (11) : 244B - 244B
  • [47] Unexpected toxicities of combined rituximab and GM-CSF in autologous transplants for CD20 positive lymphoma.
    Ehmann, WC
    Mierski, JA
    Claxton, DF
    Rybka, WB
    BLOOD, 2001, 98 (11) : 345B - 346B
  • [48] Loss of CD20 expression on CLL cells following treatment with rituximab
    Poirot, Brigitte
    Chedani, Hicham
    Abbed, Karim
    Tertian, Gerard
    Raphael, Martine
    Besson, Caroline
    HEMATOLOGIE, 2010, 16 (01): : 92 - 95
  • [49] Loss of CD20 expression in relapsed lymphomas after rituximab therapy
    Haidar, JH
    Shamseddine, A
    Salem, Z
    Mrad, YA
    Nasr, MR
    Zaatari, G
    Bazarbachi, A
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 70 (05) : 330 - 332
  • [50] CD20
    Warzynski, MJ
    Graham, DM
    Axtell, RA
    Zakem, MH
    Rotman, RK
    APPLIED IMMUNOHISTOCHEMISTRY, 1996, 4 (03): : 218 - 218
12345